Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

Objectives. Sunitinib (a second-line chemotherapeutic agent that inhibits multiple kinases, including KIT and PDGFR) is widely used in imatinib-resistant patients with gastrointestinal stromal tumors (GISTs). However, diverse responses to sunitinib have been observed in the clinic. We aimed to evalu...

Full description

Bibliographic Details
Main Authors:	Siyuan Tan, Ping Chen, Jiafu Ji, Shanshan Guo, Dapeng Yu, Tetsuya Asakawa, Yu Zhou, Masanobu Abe, Liang Zong
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	Disease Markers
Online Access:	http://dx.doi.org/10.1155/2018/1368617

Similar Items

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
by: Piotr Rutkowski, et al.
Published: (2017-12-01)

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
by: Rutkowski Piotr, et al.
Published: (2012-03-01)

Update on management of GIST and postsurgical use of imatinib
by: E Pennacchioli, et al.
Published: (2010-08-01)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
by: Bruno Vincenzi, et al.
Published: (2018-08-01)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
by: Akira Sawaki, et al.
Published: (2014-01-01)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
by: Richard Quek, et al.
Published: (2010-02-01)

Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
by: Hiroyuki Sako, et al.
Published: (2014-01-01)

Imatinib as adjuvant therapy for high risk GIST: a case report
by: Patrizia Lista, et al.
Published: (2015-10-01)

Tumor volume as an alternative response measurement for imatinib treated GIST patients.
by: Gaia Schiavon, et al.
Published: (2012-01-01)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01)

Adjuvant therapy with imatinib mesilate in a patient with intermediate risk GIST
by: Giuseppe Aprile
Published: (2015-10-01)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
by: Gaia Schiavon, et al.
Published: (2013-01-01)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
by: John T Vetto
Published: (2009-06-01)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients.
by: Gaia Schiavon, et al.
Published: (2013-01-01)

Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
by: Mariangela Parodi, et al.
Published: (2015-10-01)

Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy Imatinib y tumor del estroma gastrointestinal (GIST): un tratamiento selectivo frente a una diana molecular
by: A. Fernández, et al.
Published: (2004-10-01)

Significance of KIT and PDGFRA mutations in gastric gist imatinib - naive surgically treated patients
by: Ebrahimi Keramatollah, et al.
Published: (2019-01-01)

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
by: Sergei Boichuk, et al.
Published: (2020-06-01)

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
by: Seidel Christoph, et al.
Published: (2012-05-01)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
by: Tielen Ronald, et al.
Published: (2012-06-01)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
by: Cupissol Didier, et al.
Published: (2011-02-01)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
by: Isabelle Deshaies, et al.
Published: (2010-09-01)

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
by: Sergei Boichuk, et al.
Published: (2018-10-01)

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
by: Gronchi Alessandro, et al.
Published: (2011-09-01)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
by: Jan Yi-Yin, et al.
Published: (2006-10-01)

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
by: Xiao W, et al.
Published: (2018-05-01)

Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review
by: Schwandner Thilo, et al.
Published: (2010-06-01)

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
by: Jing Liu, et al.
Published: (2017-03-01)

GIST rectal Rectal GIST
by: Z. Valera Sánchez, et al.
Published: (2008-06-01)

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
by: Jiang Ming, et al.
Published: (2010-05-01)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
by: Nikolaos Vassos, et al.
Published: (2021-02-01)

Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
by: Lucia Tozzi
Published: (2015-10-01)

Crossing-over to imatinib 800 mg in a patient with GIST, after progression with standard dosage: a case report
by: Giuseppe Naso, et al.
Published: (2015-10-01)

Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT Patrones de extensión de los tumores del estroma gastrointestinal (GIST) tratados con imatinib (Gleevec®) mediante PET/TC con 18F-FDG
by: Eulalia Valls-Ferrusola, et al.
Published: (2012-07-01)

Gist gástrico gigante Gyant gastric GIST
by: J. Martín Gil, et al.
Published: (2009-12-01)

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
by: Thanaporn Bussabawalai, et al.
Published: (2019-01-01)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
by: Etienne Rouleau, et al.
Published: (2020-12-01)

Tratamento adjuvante nos GISTs Adjuvant treatment in GISTs
by: Laercio Gomes Lourenço, et al.
Published: (2011-09-01)

Management of GIST
by: W Wanitsuwan, et al.
Published: (2007-10-01)